Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUPARG-AMBROXOL trial in GBA-mutation Parkinson's disease
NL-OMON52316Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Ambroxol with Placebo (2 arms). Primary endpoint: MDS-UPDRS part III motor subscale in practically defined OFF-medication state. Started Jun 2023; status: recruiting.
02
Drugs
ambroxol
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON52316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52316.